Re: Schaub et al.: Intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy: results from a randomized clinical trial (Ophthalmology. 2022;129:1129-1141)

Affiliations

¹ Department of Vitreoretinal Surgery, The Rotterdam Eye Hospital, Rotterdam, the Netherlands; The Rotterdam Ophthalmic Institute, Rotterdam, The Netherlands. Electronic address: K.vanOverdam@oogziekenhuis.nl.
² VMR Institute for Vitreous Macula Retina, Huntington Beach, California; Doheny Eye Institute, Geffen School of Medicine, UCLA, Los Angeles, California.

Comment

Koen A van Overdam et al. Ophthalmology. 2023 Jun.

. 2023 Jun;130(6):e21.

doi: 10.1016/j.ophtha.2023.02.022. Epub 2023 Apr 13.

¹ Department of Vitreoretinal Surgery, The Rotterdam Eye Hospital, Rotterdam, the Netherlands; The Rotterdam Ophthalmic Institute, Rotterdam, The Netherlands. Electronic address: K.vanOverdam@oogziekenhuis.nl.
² VMR Institute for Vitreous Macula Retina, Huntington Beach, California; Doheny Eye Institute, Geffen School of Medicine, UCLA, Los Angeles, California.

No abstract available

Comment on

Intravitreal 5-Fluorouracil and Heparin to Prevent Proliferative Vitreoretinopathy: Results from a Randomized Clinical Trial.
Schaub F, Schiller P, Hoerster R, Kraus D, Holz FG, Guthoff R, Agostini H, Spitzer MS, Wiedemann P, Lommatzsch A, Boden KT, Dimopoulos S, Bemme S, Tamm S, Maier M, Roider J, Enders P, Altay L, Fauser S, Kirchhof B; PRIVENT Study Group. Schaub F, et al. Ophthalmology. 2022 Oct;129(10):1129-1141. doi: 10.1016/j.ophtha.2022.05.024. Epub 2022 Jun 7. Ophthalmology. 2022. PMID: 35680097 Clinical Trial.